How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,190 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Model-based meta-analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms. (Full text)

Model-based meta-analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms. International Prostate Symptom Score (IPSS) is a marker of lower urinary tract symptoms (LUTS) deterioration or improvement in benign prostate hyperplasia (BPH). Whereas changes in IPSS relative to baseline have been used as endpoints in clinical trials, little attention has been given to the time course of symptoms

2020 British journal of clinical pharmacology PubMed abstract

42. Impact on Sexual Function of Endoscopic Enucleation Versus Transurethral Resection of the Prostate for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: a Systematic Review and Meta‑Analysis. (Abstract)

Impact on Sexual Function of Endoscopic Enucleation Versus Transurethral Resection of the Prostate for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: a Systematic Review and Meta‑Analysis. Although the transurethral resection of the prostate (TURP) has been regarded as the gold standard surgical option for lower urinary tract symptoms due to benign prostatic hyperplasia, the endoscopic enucleation of the prostate (EEP) with novel techniques is also recommended. However (...) Manager 5.3 to compare the International Index of Erectile Function 5 (IIEF-5) scores and retrograde ejaculation rates from short to long term follow-ups.Ten articles with 1435 patients were included. EEP group showed higher IIEF-5 scores than TURP group with mean difference (MD)=1.00, 95% confidence interval (CI): 0.95-1.05 at 48 months and MD=1.08, 95% CI: 1.03-1.13 at ≥60 months, respectively. In subgroup analysis, the holmium laser enucleation of the prostate showed significantly better IIEF

2020 Journal of Endourology

43. The relationship of embolic particle size to patient outcomes in prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-regression. (Abstract)

The relationship of embolic particle size to patient outcomes in prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-regression. To explore the relationship of embolic particle size used in prostate artery embolisation (PAE) to patient outcomes.A systematic review of PubMed, EMBASE, and the Cochrane database was undertaken to identify all existing studies using PAE for benign prostatic hyperplasia (BPH). Inclusion criteria included prospective studies (...) reporting baseline and 12-month International Prostate Symptom Score (IPSS) and particle size. Exclusion criteria were overlapping studies, commentaries, abstracts, and letters. Data extraction from eligible studies included the size of embolic particle, particle material, and baseline and 12-month values for the following patient outcomes: IPSS, IPSS quality of life, urinary flow rate (Q-max), prostate volume, prostate specific antigen, and post-void residual volume. A meta-regression analysis

2020 Clinical Radiology

44. Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. (Abstract)

Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. Prostate artery embolisation (PAE) is a new minimally invasive treatment for lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). The purpose of this study was to review the efficacy and safety of PAE in the treatment of BPH with LUTS.A systematic review performed according to the PRISMA guidelines with a pre-specified search strategy for PubMed, Web of Science (...) , Cochrane Library and Embase databases protocol (PROSPERO ID: CRD42017059196). Trials studying the efficacy of prostate artery embolisation to treat LUTS with more than ten participants and follow-up longer than 6 months were included by two independent authors. Outcomes investigated were International Prostate Symptom Score (IPSS), quality of life (QoL), International Index of Erectile Function (IIEF-5), prostate volume (PV), prostate-specific antigen (PSA), peak void flow (Qmax), post-void residual

2020 European radiology

45. Efficacy and Safety of 1470-nm Diode Laser Enucleation of the Prostate in Individuals With Benign Prostatic Hyperplasia Continuously Administered Oral Anticoagulants or Antiplatelet Drugs. (Abstract)

Efficacy and Safety of 1470-nm Diode Laser Enucleation of the Prostate in Individuals With Benign Prostatic Hyperplasia Continuously Administered Oral Anticoagulants or Antiplatelet Drugs. To evaluate the efficacy and safety of 1470-nm Diode Laser Enucleation of the Prostate (DiLEP) in patients with benign prostatic hyperplasia continuously receiving oral anticoagulants or antiplatelet drugs.From January 2016 to June 2017, 144 patients were submitted to 1470-nm DiLEP, including 49 (34.0 (...) Symptom Score, quality of life score, maximum flow rate, and postvoid residual were markedly improved in both groups at 3-, 6-, and 12-month follow-up postoperatively compared with baseline values. However, no statistically significant differences were observed between the 2 groups in various assessment parameters at follow-up (P > .05).These findings demonstrated that 1470-nm DiLEP is efficient and safe in benign prostatic hyperplasia cases receiving continuous oral anticoagulant or antiplatelet

2020 Urology

46. The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume. (Abstract)

The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume. To investigate the potential mechanism of the effect of metabolic syndrome (MetS) on prostate volume (PV) and the risk of benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and the relationships of MetS and the major pathogenic factors of MetS with the clinical progression of BPH/LUTS in older Chinese men.We analyzed clinical data obtained from 506 ostensibly healthy men who

2020 Prostate

47. Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia. (Full text)

Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia. Male lower urinary tract symptoms (LUTS) occur in more than half of men above 50 years of age. LUTS were traditionally attributed to benign prostatic hyperplasia (BPH) and therefore the clinical terminology often uses LUTS and BPH interchangeably. More recently, LUTS were also linked to fibrogenic and inflammatory processes. We tested whether osteopontin (OPN), a proinflammatory and profibrotic (...) molecule, is increased in symptomatic BPH. We also tested whether prostate epithelial and stromal cells secrete OPN in response to proinflammatory stimuli and identified downstream targets of OPN in prostate stromal cells.Immunohistochemistry was performed on prostate sections obtained from the transition zone of patients who underwent surgery (Holmium laser enucleation of the prostate) to relieve LUTS (surgical BPH, S-BPH) or patients who underwent radical prostatectomy to remove low-grade prostate

2020 Prostate PubMed abstract

48. Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia

Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia Gonzalez L, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A,Bardach A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Gonzalez L, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A,Bardach A, Ciapponi A, López A, Rey-Ares L. Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rápida N° 452. 2016 Authors' conclusions The evidence found

2016 Health Technology Assessment (HTA) Database.

49. Effect of weight reduction on severity of lower urinary tract symptoms in obese men with benign prostatic hyperplasia. (Abstract)

Effect of weight reduction on severity of lower urinary tract symptoms in obese men with benign prostatic hyperplasia. 29938670 2018 12 11 2018 12 11 1024-2708 23 Suppl 2 3 2017 06 Hong Kong medical journal = Xianggang yi xue za zhi Hong Kong Med J Effect of weight reduction on severity of lower urinary tract symptoms in obese men with benign prostatic hyperplasia. 35-37 Ng C F CF Division of Urology, Department of Surgery, The Chinese University of Hong Kong. Yee C H CH Division of Urology (...) Urinary Tract Symptoms drug therapy Male Middle Aged Obesity Prospective Studies Prostatic Hyperplasia drug therapy Severity of Illness Index Weight Loss 2018 6 26 6 0 2018 6 26 6 0 2018 12 12 6 0 ppublish 29938670

2018 Hong Kong medical journal = Xianggang yi xue za zhi Controlled trial quality: uncertain

50. Bipolar or monopolar transurethral resection for benign prostatic hyperplasia? (Abstract)

Bipolar or monopolar transurethral resection for benign prostatic hyperplasia? Transurethral resection is currently considered as standard endoscopic treatment for lower urinary tract obstruction due to benign hyperplasia under 80 cc. Monopolar resection loops has been traditionally used but bipolar energy has recently displaced precedent technology. The purpose of this summary is to evaluate the efficacy and safety of both technologies.To answer this question we used Epistemonikos, the largest

2018 Medwave

51. Prostatic Artery Embolization versus Standard Surgical Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. (Full text)

Prostatic Artery Embolization versus Standard Surgical Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Prostatic artery embolization (PAE) has been introduced into clinical practice for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH-LUTS) despite a lack of high-level evidence.To perform a systematic review and meta-analysis of clinical trials comparing efficacy and safety (...) in the short term. Significant advantages regarding safety and sexual function, but clear disadvantages regarding all other patient-reported and functional outcomes were found for PAE. Large-scale randomized controlled trials including longer follow-up periods are mandatory before PAE can be considered as a standard therapy and to define the ideal indication for PAE in the management of BPH-LUTS.We reviewed the role of prostatic artery embolization (PAE) in the treatment of symptoms associated with benign

2019 European urology focus PubMed abstract

52. Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil

Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil L Lower urinary tr ower urinary tract symptoms secondary to act symptoms secondary to benign prostatic h benign prostatic hyperplasia: tadalafil yperplasia: tadalafil Evidence summary Published: 23 May 2013 nice.org.uk/guidance/esnm18 pathways Ov Overview erview The content of this evidence summary was up-to-date in May 2013. See summaries of product characteristics (SPCs), British national formulary (BNF (...) ) or the MHRA or NICE websites for up- to-date information. Key points from the evidence T adalafil is a reversible phosphodiesterase type 5 inhibitor available as an oral tablet in various strengths. In October 2012, the 5 mg tadalafil tablet (taken once daily) was granted marketing authorisation to treat signs and symptoms of benign prostatic hyperplasia in adult men. Other strength tablets (2.5 mg, 5 mg, 10 mg and 20 mg) already have marketing authorisation to treat erectile dysfunction in adult men

2013 National Institute for Health and Clinical Excellence - Advice

53. Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer. (Full text)

Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer. The role of molecular changes in the androgen receptor (AR) as AR variants (AR-Vs) is not clear in the pathophysiology of benign prostatic hyperplasia (BPH) and hormone-naïve PCa. The aim of the current work was to identify the presence of AR isoforms in benign tissue and primary PCa, and to evaluate the possible association with tumor aggressiveness and biochemical recurrence in primary PCa (...) , while AR-CTD and AR-NTD were higher in nuclei of epithelial cells from BPH. These results support the assumption that these constitutively active isoforms of AR are involved in the pathophysiology of primary PCa and BPH. The role of AR-Vs and their possible modulation by steroid tissue levels in distinct types of prostate tumors needs to be elucidated to help guide the best clinical management of these diseases.

2018 PLoS ONE PubMed abstract

54. Usefulness of the frequency-volume chart over the International Prostate Symptom Score in patients with benign prostatic hyperplasia in view of global polyuria. (Full text)

Usefulness of the frequency-volume chart over the International Prostate Symptom Score in patients with benign prostatic hyperplasia in view of global polyuria. We aimed to determine the usefulness of the frequency-volume chart over the International Prostate Symptom Score in patients with benign prostatic hyperplasia. Furthermore, we investigated the clinical characteristics suggesting that patients could benefit from frequency-volume chart assessment in addition to International Prostate (...) Symptom Score assessment.A total of 193 patients with benign prostatic hyperplasia were analyzed. The relationship between the information obtained from the frequency-volume chart and the International Prostate Symptom Score was assessed. Because the urine output per kilogram per hour was not associated with any question in the International Prostate Symptom Score questionnaire, patients were divided into 2 groups according to the presence of global polyuria, defined as urine output >40 mL·kg-1·h-1

2018 PLoS ONE PubMed abstract

55. Accuracy of a "Single Question Nocturia Score" compared to the "International Prostate Symptoms Score" in the evaluation of lower urinary tract symptoms in benign prostatic hyperplasia: A study performed at Ndola Teaching Hospital, Ndola, Zambia. (Full text)

Accuracy of a "Single Question Nocturia Score" compared to the "International Prostate Symptoms Score" in the evaluation of lower urinary tract symptoms in benign prostatic hyperplasia: A study performed at Ndola Teaching Hospital, Ndola, Zambia. The International Prostate Symptom Score (IPSS) is a useful tool approved by the World Health Organisation and the American Urological Association to measure the severity of lower urinary tract symptoms (LUTS). Although commonly used in urological (...) symptoms in men with Benign prostatic hyperplasia(BPH).The study was designed as a cross-sectional study using researcher-administered IPSS and SQNS questionnaires. The sensitivity, specificity, and correlation coefficient were used to compare the results obtained. Sensitivity was defined as the ability of the SQNS to detect severe-to-moderate symptoms, whereas specificity was defined as the ability of the SQNS to detect mild-to-no symptoms.We recruited 162 patients with an age range between 50 and 88

2018 PLoS ONE PubMed abstract

56. Re: Comparison of Prostatic Artery Embolization (PAE) Versus Transurethral Resection of the Prostate (TURP) for Benign Prostatic Hyperplasia: Randomised, Open Label, Non-inferiority Trial. (Abstract)

Re: Comparison of Prostatic Artery Embolization (PAE) Versus Transurethral Resection of the Prostate (TURP) for Benign Prostatic Hyperplasia: Randomised, Open Label, Non-inferiority Trial. 30082149 2019 02 07 2019 02 15 1873-7560 74 6 2018 12 European urology Eur. Urol. Re: Comparison of Prostatic Artery Embolization (PAE) Versus Transurethral Resection of the Prostate (TURP) for Benign Prostatic Hyperplasia: Randomised, Open Label, Non-inferiority Trial. 844 S0302-2838(18)30533-5 10.1016 (...) /j.eururo.2018.07.020 Madersbacher Stephan S Department of Urology, Kaiser Franz Josef Hospital, Sigmund Freud Private University, Vienna, Austria. Electronic address: stephan.madersbacher@wienkav.at. eng Journal Article Comment 2018 08 03 Switzerland Eur Urol 7512719 0302-2838 IM BMJ. 2018 Jun 19;361:k2338 29921613 Arteries Embolization, Therapeutic Humans Male Prostatic Hyperplasia surgery Transurethral Resection of Prostate 2018 07 04 2018 07 11 2018 8 8 6 0 2019 2 8 6 0 2018 8 8 6 0 ppublish

2019 European Urology Controlled trial quality: uncertain

57. A systematic review and meta-analysis of efficacy and safety following holmium laser enucleation of prostate and transurethral resection of prostate for benign prostatic hyperplasia. (Abstract)

A systematic review and meta-analysis of efficacy and safety following holmium laser enucleation of prostate and transurethral resection of prostate for benign prostatic hyperplasia. Transurethral resection of prostate (TURP) still remains the "gold standard" surgical treatment for benign prostatic hyperplasia (BPH). In recent years, holmium laser enucleation of prostate (HoLEP) gets more and more popularity in the world. Our objective is to compare the efficacy and safety of HoLEP and TURP (...) for BPH. Eleven studies met our eligibility criteria including 1339 patients. The prostate sizes of the all included studies were smaller than 100 g. Overall, in patients with small to mid-sized prostates, HoLEP offers safer clinical outcomes with less blood drop and potentially better long-term relief of bladder outlet obstruction.Copyright © 2019 Elsevier Inc. All rights reserved.

2019 Urology

58. Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis. (Full text)

Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis. To compare the clinical efficiency and safety of transurethral resection of the prostate (TURP) and prostatic artery embolization (PAE) for the treatment of Benign prostatic hyperplasia (BPH).We searched PUBMED, EMBASE and the Cochrane Central Register for studies from May 1998 to May 2018 for studies comparing the efficiency and safety of TURP with PAE (...) . Four studies met the inclusion criteria for our meta-analysis. After data extraction and quality assessment, we used RevMan 5.2 to pool the data.A total of four studies involving 506 patients were included in our meta-analysis. The pooled data showed that the Qmax was higher in TURP group than PAE with a significant difference (WMD:4.66, 95%CI 2.54 to 6.79, P < 0.05). The postoperative QOL was lower in the TURP than PAE group (WMD: -0.53, 95%CI -0.88 to - 0.18, P < 0.05). The postoperative prostate

2019 BMC Urology PubMed abstract

59. Thulium (Tm:YAG) laser vaporesection of prostate and bipolar transurethral resection of prostate in patients with benign prostate hyperplasia: a systematic review and meta-analysis. (Abstract)

Thulium (Tm:YAG) laser vaporesection of prostate and bipolar transurethral resection of prostate in patients with benign prostate hyperplasia: a systematic review and meta-analysis. Thulium laser vaporesection (ThuVARP) and bipolar transurethral resection of the prostate (B-TURP) are novel surgeries for benign prostate hyperplasia (BPH). This paper is a systematic review and analysis of literatures comparing efficacy indicators, operative parameters, as well as safety indicators between ThuVARP (...) and B-TURP for the treatment of BPH. A systematic search of electronic databases, including PubMed, the Cochrane Library, Web of Science, Embase, and China National Knowledge Internet (CNKI), was carried out up to December 1, 2015 (updated on March 1, 2016). The captivating outcomes included basic clinical characteristics, perioperative parameters, local complications, and efficacy indicators which included International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax

2019 Lasers in medical science

60. Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis. (Abstract)

Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis. 31522236 2019 09 15 1433-8726 2019 Sep 14 World journal of urology World J Urol Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis. 10.1007/s00345-019-02954-w Zhou Zhongbao Z http://orcid.org/0000-0002-9810-8145 School of Clinical Medicine, Binzhou Medical

2019 World journal of urology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>